Ichnos Glenmark Innovation’s phase 1 study of trispecific antibody shows strong results in myeloma treatment

Ichnos Glenmark Innovation (IGI), a collaboration between Glenmark Pharmaceuticals Limited and Ichnos Sciences Inc., has unveiled promising results from its Phase 1 clinical trial involving ... Read More